First-in-Human Transcatheter Tricuspid Valve Repair: 30-Day Follow-Up Experience With the Mistral Device

Keyphrases

• Mistral 100%
• First-in-human 100%
• Transcatheter Tricuspid Valve Replacement 100%
• Tricuspid Regurgitation 28%
• High Surgical Risk 28%
• Tricuspid Insufficiency 28%
• Procedural 14%
• Adverse Events 14%
• Echocardiography Guidance 14%
• Spiral Shape 14%
• Capacity Function 14%
• Exercise Capacity 14%
• Safety Efficacy 14%
• Safer Method 14%
• Right Ventricular Function 14%
• Right Ventricular Fractional Area Change 14%
• Safety Performance 14%
• Tricuspid Valve Repair 14%
• Severe Tricuspid Regurgitation 14%
• Single Device 14%
• Tricuspid Repair 14%
• Transcatheter Repair 14%
• Chordae Tendineae 14%
• Effective Regurgitant Orifice Area 14%
• Transesophageal Echocardiography 14%
• First-in-human Study 14%
• 6-minute Walk Test (6MWT) 14%
• Short-term Outcomes 14%
• Vena Contracta Area 14%
• Regurgitant Volume 14%
• Tricuspid Valve 14%
• Kansas City Cardiomyopathy Questionnaire 14%
• Minimally Invasive Methods 14%
• New York Heart Association Functional Class 14%

Medicine and Dentistry

• Dermatan Sulfate 100%
• Tricuspid Valve Repair 100%
• Tricuspid Insufficiency 71%
• Surgical Risk 28%
• Adverse Event 14%
• Human Study 14%
• Transesophageal Echocardiography 14%
• Six Minute Walk Test 14%
• Exercise 14%
• Tricuspid Valve 14%
• New York Heart Association Class 14%
• Right Ventricular Function 14%
• Chordae Tendineae 14%
• Myocardial Disease 14%